- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02024672
Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed Immediately After Giving Birth
Ultrasound Surveillance of IUDs Placed Immediately Postpartum
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The goal of this study is to document the expected ultrasound appearance of intrauterine devices (IUDs) placed immediately postpartum. This practice has been shown to be safe and effective, but little is known about long-term follow up for IUDs placed in this setting. Because IUD strings will not be visualized for many patients after immediate postpartum IUD placement, sonographic imaging will likely be required for the majority of patients to determine expulsion. However, the ultrasound appearance of these IUDs, placed immediately after birth and before uterine involution, may be different than those IUDs placed outside of the postpartum period. To our knowledge no other study has documented expected ultrasound appearance of IUDs placed in the immediate postpartum period.
The specific aims of this study are to: 1. document normal appearance of IUDs on ultrasound after immediate postpartum placement; 2. document if this appearance changes over time; and 3. determine if location on ultrasound is associated with side effects or expulsion.
Study design This is a prospective, observational study. All patients who have an IUD (either copper or levonorgestrel) placed immediately postpartum (within 10 minutes of delivery of placenta) after either Cesarean or vaginal delivery at Mount Sinai Medical Center and at Elmhurst Hospital Center will be eligible to participate in the study.
Study visits will include a speculum exam for IUD string check at 6 weeks, and ultrasounds to evaluate IUD position at the following time points: 6-10 weeks following placement, 3 months following placement (with inclusion up to 6 months), and 12 months following placement (with inclusion up to 15 months).
The ultrasound will document the following: size and position of uterus, IUD-Myometrium distance, IUD-endometrium distance, IUD-fundus distance and position of IUD. When participants present for the scheduled ultrasound visits, they will be asked to return with the completed symptom diary as well, to assess bleeding and pain.
Study Endpoints IUD expulsion, removal, or completion of the 12-15 month follow up visit will be the study endpoints. The participant will be withdrawn from the study if IUD expulsion occurs, or if she requests IUD removal for any reason. Participants will also be able to withdraw from the study at any time if they no longer wish to participate, but they may keep their IUD in place if desired.
Study procedures At the routine 6 week postpartum visit for all patients, pelvic and speculum exam will be performed as per normal clinical routine, and visualization of IUD strings at the cervical os will be documented. If IUD strings are not visualized, an ultrasound will be performed by the clinical provider to confirm presence or absence of IUD within the uterus.
A formal ultrasound to evaluate IUD position will be scheduled in the FPA gynecologic ultrasound unit or in the Gynecology clinic at EHC at the following time points: 6-10 weeks following placement, 3 months following placement (with inclusion up to 6 months), and 12 months following placement (with inclusion up to 15 months). The formal ultrasound will document the following: size and position of uterus, endometrial stripe (EMS) thickness, IUD-Myometrium distance, IUD-endometrium distance, IUD-fundus distance and position of IUD.
Immediate postpartum placement of IUDs is a relatively new clinical practice in the United States; as such there is no recommended or "standard" follow up protocol in this situation. For IUDs placed outside of the postpartum period, the standard follow up is a string check (speculum exam to confirm presence of strings at cervical os) 2-6 weeks after IUD placement. If strings are not visible, or if the patient experiences symptoms concerning for expulsion, a transvaginal ultrasound will be performed. Once correct placement is confirmed by ultrasound, patients without visible strings generally have ultrasounds yearly to confirm placement. Based on this standard practice, patients with visible strings will have the ultrasound only for research purposes. Additionally, the three month ultrasound will be only for research purposes, even in those without visible strings.
When participants present for the scheduled ultrasound visits, they will be asked to return with the completed symptom diary as well.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
Elmhurst, New York, United States, 11373
- Elmhurst Hospital Center
-
New York, New York, United States, 10029
- ICAHN School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women >18 years of age
- English or Spanish speaking
- Desire postpartum IUD placement, either copper IUD or levonorgestrel IUD
Exclusion Criteria:
- Contraindications for IUD use (CDC MEDICAL Eligibility Criteria category 3 or 4 for specific IUD)
- Positive Chlamydia or gonorrhea cervical cultures in past 3 months
- Immediate postpartum hemorrhage
- Premature rupture of membranes (PROM) >12h or diagnosis of endometritis
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Immediate postpartum placement of IUD
Women who plan to have an IUD placed at the time of cesarean section or vaginal delivery, or women who have had an IUD placed at the time of cesarean section or vaginal delivery.
|
pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
IUD-endometrial distance association with expulsion risk
Time Frame: at 6 weeks after IUD placement
|
at 6 weeks after IUD placement
|
|
IUD-endometrial distance association with expulsion risk
Time Frame: at 3 months after IUD placement
|
at 3 months after IUD placement
|
|
IUD-endometrial distance association with expulsion risk
Time Frame: at 1 year after IUD placement
|
at 1 year after IUD placement
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Expected normal appearance of IUD on ultrasound and change in appearance over time
Time Frame: 6 weeks after IUD placement
|
6 weeks after IUD placement
|
|
Expected normal appearance of IUD on ultrasound and change in appearance over time
Time Frame: 3 months after IUD placement
|
3 months after IUD placement
|
|
Expected normal appearance of IUD on ultrasound and change in appearance over time
Time Frame: 1 year after IUD placement
|
1 year after IUD placement
|
|
IUD endometrial distance association with side effects
Time Frame: 6 weeks after IUD placement
|
6 weeks after IUD placement
|
|
IUD endometrial distance association with side effects
Time Frame: 1 year after IUD placement
|
1 year after IUD placement
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Britt Lunde, MD, MPH, ICAHN School of Medicine at Mount Sinai
Publications and helpful links
General Publications
- ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol. 2011 Jul;118(1):184-196. doi: 10.1097/AOG.0b013e318227f05e. No abstract available.
- Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone. 4th edition. Geneva: World Health Organization; 2010. Available from http://www.ncbi.nlm.nih.gov/books/NBK138639/
- Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep. 2012 Jun 22;61(24):449-52.
- Levi E, Cantillo E, Ades V, Banks E, Murthy A. Immediate postplacental IUD insertion at cesarean delivery: a prospective cohort study. Contraception. 2012 Aug;86(2):102-5. doi: 10.1016/j.contraception.2011.11.019. Epub 2012 Jan 20.
- Faundes D, Bahamondes L, Faundes A, Petta C, Diaz J, Marchi N. No relationship between the IUD position evaluated by ultrasound and complaints of bleeding and pain. Contraception. 1997 Jul;56(1):43-7. doi: 10.1016/s0010-7824(97)00072-3.
- Faundes D, Perdigao A, Faundes A, Bahamondes L, Petta CA. T-shaped IUDs accommodate in their position during the first 3 months after insertion. Contraception. 2000 Oct;62(4):165-8. doi: 10.1016/s0010-7824(00)00167-0.
- Shimoni N, Davis A, Westhoff C. Can ultrasound predict copper IUD expulsion after medical abortion? Poster presentation at NAF 2012 conference, Columbia University Medical Center.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- GCO 13-1557
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Montefiore Medical CenterSociety of Family PlanningCompletedContraception | Breastfeeding | Postpartum ContraceptionUnited States
Clinical Trials on Immediate postpartum placement of IUD
-
University of North Carolina, Chapel HillSociety of Family PlanningCompletedCesarean Section | Intrauterine DevicesUnited States
-
University of New MexicoSociety of Family PlanningCompletedContraceptionUnited States
-
Assiut UniversityNot yet recruiting
-
Ohio State UniversityRecruitingPregnancy, High Risk | Gestational Diabetes | Pre-Gestational Diabetes | Pregnancy in Diabetic | Type2diabetes | Gestational Diabetes Mellitus in the PuerperiumUnited States
-
Universidade Católica PortuguesaDanilo FernandesCompleted
-
Università Vita-Salute San RaffaeleCompleted
-
Yasser AhmedCompletedMarginal Bone LossLebanon
-
Kafrelsheikh UniversityRecruitingImmediate Implant PlacementEgypt
-
Ain Shams Maternity HospitalCompletedContraception | IUDEgypt
-
University of BernSuspendedComplications | Patient Reported Outcome Measures | Cost-Benefit Analysis | Cost-effectiveness | Esthetic Zone | Single Tooth Dental Implant | Single Tooth Lost | Accuracy of Dental Implants | Dimensional Changes | Implant Survival and Success | Frequency of Treatment ProtocolSwitzerland